Abiopharma

News list

(75% Positive) CADRENAL THERAPEUTICS, INC. (CVKD) Provides Update on trial for heparin-induced thrombocytopenia (HIT)

Full text

News bot April 30, 2026, 12:45 p.m.
📋 CADRENAL THERAPEUTICS, INC. (CVKD) - Clinical Trial Update

Filing Date: 2026-04-30

Accepted: 2026-04-30 08:40:33

Event Type: Clinical Trial Update
Event Details:
CADRENAL THERAPEUTICS, INC. (CVKD) Announces Clinical Trial Update CADRENAL THERAPEUTICS, INC. (CVKD) provided an update on its clinical development programs. Clinical Development Highlights:
Drug Program: trial, inhibitor
Diseases/Conditions: heparin-induced thrombocytopenia (HIT)
Clinical Stage: Phase 3, Phase 2
Collaboration: Company
targeting the underlying pathophysiologic mechanisms that current therapies do not,” said James Ferguson, M.D., Chief Medical Officer of Cadrenal Therapeutics. “Interrupting the vicious cycle of platelet activation in HIT with CAD-1005
💼 Business Developments:

No business developments data available.
Structured Data:
- Company Name: CADRENAL THERAPEUTICS, INC.
- Ticker Symbol: CVKD